| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 10/28/2004 | US20040214874 Inhibition of protein-tyrosine kinase cmet to block cancer cell proliferation, oral bioavailibility; 2-(2,6-dichlorophenyl)-4-phenyl-5-(pyrimidin-4yl)-1H-imidazoles |
| 10/28/2004 | US20040214871 Treating cancer with a synergistic mixtures; anticarcinogenic agents; epothilone has secondary amide instead of an ester |
| 10/28/2004 | US20040214868 Treatment or prevention of type 2 diabetes; chemical synthesis; 2-[ benzoyl]aminopyridine-5-carboxylate derivatives |
| 10/28/2004 | US20040214862 A N'-hydroxy-terephthalamide derivatives; histone deacetylase enzyme inhibitors; ANTIPROLIFERATIVE AGENTS; ANTITUMOR AGENTS |
| 10/28/2004 | US20040214859 Zolpidem hemitartrate |
| 10/28/2004 | US20040214858 For use in short-term therapy of insomnia |
| 10/28/2004 | US20040214857 Substituted benzimidazoles and imidazo-[4,5]-pyridines |
| 10/28/2004 | US20040214853 Analgesics; side effect reduction; antidiabetic agents; central nervous system disorders |
| 10/28/2004 | US20040214846 A heteroaryl carbamic acid, secondary amide or amine, or phthalimidoyl derivatives; prevent from getting the disease or condition; cognitive impairment, Down's syndrome, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type, cerebral amyloid angiopathy, neurodegenerative disease |
| 10/28/2004 | US20040214844 N4-acylcytosine nucleosides for treatment of viral infections |
| 10/28/2004 | US20040214842 comprises opioid analgesic agent (morphine, codeine, fentanyl, and/or methadone) and compound that binds to SS1 or SS2 subunit of sodium channel, such as tetrodotoxin and saxitoxin; side effect reduction |
| 10/28/2004 | US20040214834 Pyrazolo-pyridines for the treatment of herpes infections |
| 10/28/2004 | US20040214831 cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction |
| 10/28/2004 | US20040214830 2,7-Substituted octahydro-1H-pyrido[1,2-a]pyrazine derivatives as ligands for serotonin receptors |
| 10/28/2004 | US20040214822 Substituted 4-aminocyclohexanol compounds |
| 10/28/2004 | US20040214821 Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| 10/28/2004 | US20040214816 Substituted imidazoles useful in the treatment of inflammatory diseases |
| 10/28/2004 | US20040214815 Therapeutic compounds |
| 10/28/2004 | US20040214814 Pyrazole compounds useful as protein kinase inhibitors |
| 10/28/2004 | US20040214793 In aitu applying to bone joints |
| 10/28/2004 | US20040214765 Methods and means for inhibition of CDK4 activity |
| 10/28/2004 | US20040214759 Compositions and methods of use for a fibroblast growth factor |
| 10/28/2004 | US20040214746 Pharmaceutical composition of a tachykinin receptor antagonist |
| 10/28/2004 | US20040214332 Stable, multipotent transgenic nervous system progenitor tissue for treatment and prevention of neurodegenerative disorders |
| 10/28/2004 | US20040214321 Agent for inducing conversion of intestinal cells into insulin-producing cells and antidiabetic drug |
| 10/28/2004 | US20040214286 Comprises nucleotide sequences coding cell growth factors for use in developing modulators for treatment of cell proliferative, arthritic, skin and vision defects; immunotherapy |
| 10/28/2004 | US20040214283 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof |
| 10/28/2004 | US20040214275 Von willebrand factor (vmf)-cleaving enzyme |
| 10/28/2004 | US20040214264 Comprises nucleotide sequences coding dimethylarginine dimethylaminohydrolase-1 protein (DDAH1) for use in identifying modulators for treatment of diabetes and cardiovascular disorders |
| 10/28/2004 | US20040214195 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| 10/28/2004 | US20040213862 comprising Morinda citrifolia fruit juice; treatment of allergies or asthma; increasing glucose production |
| 10/28/2004 | US20040213855 Pharmaceutical composition for the treatment of acute disorders |
| 10/28/2004 | US20040213834 Pharmacological preparation made from a nanopatriculate mesomorphous polyelectrolyte lipid complex and at least one active ingredient |
| 10/28/2004 | US20040213797 Conjugates for the modulation of immune responses |
| 10/28/2004 | US20040213785 Stabilizedpreparations containing antibody |
| 10/28/2004 | US20040213762 A viral vector containing a nucleic acid sequence encoding V3 polypeptide or a biologically active fragment of the V3 |
| 10/28/2004 | US20040213756 Methods and compositions to treat myocardial conditions |
| 10/28/2004 | US20040213753 administrating to a skin or hair of a candidate a sponge protein hydrolysate which is a product by acidic hydrolysis of sponge skeleton fibers (spongin fibers) obtained from refined sponges as the raw material in an amount effective to stimulate cell growth of the skin or hair |
| 10/28/2004 | US20040213442 Novel fatty acids analogous |
| 10/28/2004 | CA2526899A1 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
| 10/28/2004 | CA2522076A1 Method for identifying modulators of g protein coupled receptor signaling |
| 10/27/2004 | EP1471074A2 Methods for improving the conformation of proteins by means of reducing agents |
| 10/27/2004 | EP1471067A1 Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent |
| 10/27/2004 | EP1471065A1 Novel 1,2,4-triazole compound |
| 10/27/2004 | EP1471064A1 Coumarin derivatives, process for their production and use thereof |
| 10/27/2004 | EP1471056A1 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 10/27/2004 | EP1471055A1 6-phenylpyridyl-2-amine derivatives |
| 10/27/2004 | EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 10/27/2004 | EP1471049A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| 10/27/2004 | EP1470820A1 Carbon dioxide compositions for external use and process for producing the same |
| 10/27/2004 | EP1470257A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470246A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| 10/27/2004 | EP1470231A2 Methods of obtaining isoform specific expression in mammalian cells |
| 10/27/2004 | EP1470155A2 Pluripotency determining factors and uses thereof |
| 10/27/2004 | EP1470148A2 Double-stranded oligonucleotides |
| 10/27/2004 | EP1470143A1 Compounds that inhibit factor xa activity |
| 10/27/2004 | EP1470138A1 Mmp inhibitors |
| 10/27/2004 | EP1470127A1 N, n'-dimethylated n-confused porphyrins |
| 10/27/2004 | EP1470126A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| 10/27/2004 | EP1470124A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES |
| 10/27/2004 | EP1470122A1 Rho-kinase inhibitors |
| 10/27/2004 | EP1470121A1 Pyrimidine derivatives as rho-kinase inhibitors |
| 10/27/2004 | EP1470120A1 N-oxyde of n-phenyl-2-pyrimidine-amine derivatives |
| 10/27/2004 | EP1470115A1 Treatment of male sexual dysfunction |
| 10/27/2004 | EP1470113A1 Pyrimidinone viral polymerase inhibitors |
| 10/27/2004 | EP1470112A1 Substituted pyridazinones as inhibitors of p38 |
| 10/27/2004 | EP1470109A1 Metabolites of (3- [(4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl -phenoxy)-acetic acid |
| 10/27/2004 | EP1470107A2 Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists |
| 10/27/2004 | EP1470104A2 Novel compounds that inhibit factor xa activity |
| 10/27/2004 | EP1470101A1 New opioid derivative |
| 10/27/2004 | EP1469887A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 10/27/2004 | EP1469880A2 Method for reducing morbidity and mortality in critically ill patients |
| 10/27/2004 | EP1469878A2 Fgfr agonists |
| 10/27/2004 | EP1469877A2 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies |
| 10/27/2004 | EP1469875A1 Compositions and methods for modulating connexin hemichannels |
| 10/27/2004 | EP1469874A1 The use of melagatran for the manufacture of a medicament for the treatment of type 1 diabetes mellitus |
| 10/27/2004 | EP1469873A2 Peptidomimetic inhibitors of post-proline cleaving enzymes |
| 10/27/2004 | EP1469867A1 Method of treating halitosis |
| 10/27/2004 | EP1469860A2 Anti-cancer combination and use thereof |
| 10/27/2004 | EP1469859A1 Use of polyunsaturated ketones for the treatment of psoriasis |
| 10/27/2004 | EP1469857A1 Use of pde5 inhibitors in the treatment of scarring and fibrosis |
| 10/27/2004 | EP1469856A2 8-heteroaryl xanthine adenosine a sb 2b /sb receptor antagonists |
| 10/27/2004 | EP1469854A1 Condensed heterocyclic compounds |
| 10/27/2004 | EP1469852A2 Nitric oxide donors for treatment of disease and injury |
| 10/27/2004 | EP1469851A1 Melanocortin receptor agonists |
| 10/27/2004 | EP1469849A1 Treating stress response with chemokine receptor ccr5 modulators |
| 10/27/2004 | EP1469847A1 Combinations comprising epothilones and anti-metabolites |
| 10/27/2004 | EP1469846A2 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 10/27/2004 | EP1469842A2 Bicyclic cb2 cannabinoid receptor ligands |
| 10/27/2004 | EP1469839A2 Transmucosal delivery of proton pump inhibitors |
| 10/27/2004 | EP1469836A1 Increased-dosage nelfinavir tablet and method of making same |
| 10/27/2004 | EP1469834A1 Multi-stage oral drug controlled-release system |
| 10/27/2004 | EP1469833A2 Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
| 10/27/2004 | EP1469831A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors |
| 10/27/2004 | EP1469830A2 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
| 10/27/2004 | EP1469829A2 Immediate release dosage forms containing solid drug dispersions |
| 10/27/2004 | EP1469812A2 Oral insulin therapy |
| 10/27/2004 | EP1469769A2 Novel compositions and methods for cancer |
| 10/27/2004 | EP1469743A1 Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients |